Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:47PM ET
10.73
Dollar change
+0.24
Percentage change
2.26
%
Index- P/E- EPS (ttm)-1.62 Insider Own2.41% Shs Outstand365.24M Perf Week12.92%
Market Cap3.92B Forward P/E2.69 EPS next Y3.99 Insider Trans-0.07% Shs Float356.39M Perf Month16.60%
Income-592.00M PEG- EPS next Q0.69 Inst Own79.18% Short Float6.91% Perf Quarter38.42%
Sales8.76B P/S0.45 EPS this Y12.80% Inst Trans19.53% Short Ratio10.33 Perf Half Y30.82%
Book/sh-2.80 P/B- EPS next Y1.98% ROA-2.23% Short Interest24.64M Perf Year43.61%
Cash/sh2.63 P/C4.07 EPS next 5Y2.60% ROE- 52W Range5.57 - 10.49 Perf YTD33.76%
Dividend Est.- P/FCF5.06 EPS past 5Y32.76% ROI-2.81% 52W High2.26% Beta0.84
Dividend TTM- Quick Ratio0.94 Sales past 5Y1.03% Gross Margin58.48% 52W Low92.58% ATR (14)0.32
Dividend Ex-DateNov 10, 2010 Current Ratio1.30 EPS Y/Y TTM-160.23% Oper. Margin18.34% RSI (14)77.31 Volatility3.91% 3.30%
Employees20270 Debt/Eq- Sales Y/Y TTM7.79% Profit Margin-6.76% Recom2.83 Target Price9.83
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q90.57% Payout- Rel Volume1.38 Prev Close10.49
Sales Surprise4.99% EPS Surprise-4.77% Sales Q/Q9.80% EarningsFeb 22 BMO Avg Volume2.39M Price10.73
SMA2013.25% SMA5021.71% SMA20031.70% Trades Volume2,702,358 Change2.26%
Date Action Analyst Rating Change Price Target Change
Sep-20-23Upgrade Jefferies Hold → Buy $9 → $16
Jun-16-23Downgrade TD Cowen Outperform → Market Perform
Jul-29-22Downgrade Truist Buy → Hold
Jul-29-22Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $5
Jul-28-22Downgrade JP Morgan Overweight → Neutral
Jun-13-22Resumed JP Morgan Overweight $12
Mar-24-21Downgrade BofA Securities Neutral → Underperform $27
Feb-17-21Upgrade RBC Capital Mkts Sector Perform → Outperform $26 → $42
Jan-22-21Downgrade Piper Sandler Overweight → Neutral $25 → $30
Sep-17-20Upgrade BofA Securities Underperform → Neutral $19
Today 02:19PM
05:23AM
Mar-15-24 09:50AM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
08:00AM Loading…
Mar-01-24 08:00AM
Feb-27-24 03:27AM
Feb-23-24 12:25PM
11:53AM
Feb-22-24 11:30AM
10:03AM
09:30AM
08:25AM
07:33AM
07:33AM
07:00AM Loading…
07:00AM
Feb-21-24 12:10PM
07:26AM
Feb-19-24 09:15AM
Feb-15-24 10:00AM
Feb-12-24 08:00AM
Feb-08-24 10:59AM
Feb-07-24 12:00PM
Feb-01-24 04:10PM
08:00AM
Jan-31-24 04:00PM
Jan-30-24 05:54PM
08:00AM
Jan-18-24 04:50PM
08:00AM
11:15AM Loading…
Jan-08-24 11:15AM
Dec-22-23 10:23AM
Dec-21-23 07:00AM
Dec-18-23 09:40AM
08:00AM
Dec-13-23 07:43AM
Dec-11-23 09:55AM
Dec-05-23 08:00AM
Nov-30-23 09:40AM
Nov-24-23 09:55AM
Nov-13-23 09:55AM
Nov-10-23 12:42PM
08:00AM
Nov-08-23 08:00AM
Nov-03-23 02:03PM
12:47PM
Nov-02-23 04:13PM
11:00AM
09:41AM
08:34AM
07:00AM
Nov-01-23 12:22PM
10:43AM
10:40AM
09:30AM
07:07AM
Oct-31-23 02:58AM
Oct-30-23 04:35PM
Oct-26-23 10:02AM
10:02AM
08:00AM
Oct-25-23 10:02AM
Oct-20-23 05:20PM
Oct-17-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-04-23 08:00AM
Sep-29-23 10:15AM
Sep-26-23 08:54AM
Sep-21-23 11:16AM
08:00AM
Sep-20-23 11:25AM
10:50AM
Sep-19-23 04:32PM
02:37PM
01:46PM
11:47AM
Sep-18-23 05:45PM
Sep-15-23 08:25AM
Sep-12-23 08:00AM
Sep-11-23 04:04PM
09:04AM
08:00AM
Sep-06-23 06:16PM
Aug-25-23 09:40AM
Aug-23-23 03:49AM
Aug-22-23 09:19AM
Aug-15-23 06:00AM
Aug-09-23 08:19AM
Aug-08-23 10:00AM
08:15AM
07:40AM
Aug-05-23 01:58PM
06:23AM
Aug-04-23 01:17PM
Aug-03-23 10:30AM
09:55AM
08:47AM
07:00AM
Aug-02-23 12:51PM
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carson SeanaEVP, General CounselMar 04 '24Sale9.806,31361,867499,905Mar 04 04:16 PM
Carson SeanaEVP, General CounselDec 05 '23Sale7.382201,624382,925Dec 05 04:35 PM
Carson SeanaEVP, General CounselNov 06 '23Sale7.6143327384,836Nov 06 05:06 PM
Carson SeanaEVP, General CounselSep 06 '23Sale8.286,68555,352385,213Sep 06 04:33 PM